|Articles|September 26, 2022
How Sponsors and CROs can Fully Benefit from the Permanent Shift Toward Decentralized Clinical Trials Brought About by the COVID-19 Pandemic
Author(s)PCM Trials
There is a growing body of evidence that hybrid and decentralized clinical trials are here to stay. What was once a nice-to-have is quickly transforming into a must-have. The catalyst for this dramatic shift was the COVID-19 pandemic. To aid sponsors and CROs in fully realizing the benefits of decentralized clinical trial methods moving forward, this whitepaper extracts the lessons learned from the pandemic and their implications for clinical trials now and in the future.
Trending on Applied Clinical Trials Online
1
From Perspective to Action: Addressing the Real Cost Pressures in Clinical Trial Budgeting
2
Fortrea to Acquire Worldwide Clinical Trials' Early Phase Services Division in $45 Million Deal
3
FDA Reaffirms GCP Standards Amid Growing Concerns Over Foreign Clinical Trial Data
4
Why Time Savings Is the Largest Driver of RBQM's Financial Value
5